Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis

Company Overview

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com

Key Stats

• Today's Range: 220.75 to 230
• 50-Day Range: 167 to 250
• 52-Week Range: 85 to 290
• Volume: 21,897 shs
• Average Volume: 48,859 shs
• Market Capitalization: £308.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FARN Stock Analysis - Frequently Asked Questions

How have FARN shares performed this year?

Faron Pharmaceuticals Oy's stock was trading at GBX 207 at the beginning of 2025. Since then, FARN stock has increased by 11.1% and is now trading at GBX 230.
View the best growth stocks for 2025 here.

How do I buy shares of Faron Pharmaceuticals Oy?

Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Faron Pharmaceuticals Oy own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:FARN
• CIK: N/A
• Web: www.faron.com
• Phone: +358-2-4695151
• Fax: N/A
• Employees: 34
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (37.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-60,233,480.81
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 0.46%
• Return on Assets: -70.00%

Debt

• Debt-to-Equity Ratio: 922.55
• Current Ratio: 1.45
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 11.50 per share
• Price / Cash Flow: 20.00
• Book Value: GBX 1,957.36 per share
• Price / Book: 0.12

Miscellaneous

• Outstanding Shares: 134,251,928
• Free Float: N/A
• Market Cap: £308.78 million
• Optionable: Not Optionable
• Beta: 0.36